DSM-V

Wonder Tech's Breakthrough in Language Agnostic Voice AI to Bring Scalable Depression Screening to One Billion People Globally

Retrieved on: 
Tuesday, November 28, 2023
Ministry, DSM-IV codes, Mental, Schizophrenia, Depression, B2B, GDP, Risk, Cardiovascular disease, Insurance, Patient, National University Hospital, Tech, NUH, Anxiety, Bipolar disorder, Diagnosis, Cancer, Speech, SingHealth, Software as a service, PTE, Mental health, Biomarker, AI, DSM-V, Approximation error, Human, Ministry of Health, Medical device, Nursing, Health

LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening.

Key Points: 
  • LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening.
  • The AI model, which identifies depression through detecting nuanced vocal changes, has reached an industry-leading 83% in detection accuracy, surpassing the 80% threshold required for clinical depression detection.
  • With this milestone, Wonder Tech has proven its potential to enable a scalable and adaptable diagnostic tool to help the one billion people affected by mental health disorders worldwide.
  • Wonder Tech also received financial and clinical support from Singapore's Ministry of Health to scale out the solution with leading mental health institutes.

Houston Law Firm to Award Autism Scholarship for Higher Education

Retrieved on: 
Thursday, May 4, 2023
Insurance, Communication, Autism spectrum, Education, Social, Spectrum, Policy, Privacy, Centers for Disease Control and Prevention, ASD, Child, Motivation, Diagnosis, DSM-V, Nursing, Residential care

HOUSTON, May 4, 2023 /PRNewswire-PRWeb/ -- The Fitts Law Firm, a Houston personal injury and insurance law firm, has announced that it will be awarding an educational scholarship open to individuals diagnosed with autism (Autism Spectrum Disorder or ASD). The $1,000 tuition scholarship will assist the winning entrant in attending a post-secondary school, i.e., a college, junior college, or university.

Key Points: 
  • HOUSTON, May 4, 2023 /PRNewswire-PRWeb/ -- The Fitts Law Firm , a Houston personal injury and insurance law firm, has announced that it will be awarding an educational scholarship open to individuals diagnosed with autism (Autism Spectrum Disorder or ASD).
  • The $1,000 tuition scholarship will assist the winning entrant in attending a post-secondary school, i.e., a college, junior college, or university.
  • The Fitts Law Firm seeks to encourage those with autism spectrum disorder to expand their options going forward.
  • Along with diagnosis and treatment, the firm is hopeful that this will provide the winning applicant with additional motivation to continue with their education, which is often cut short for those with autism.

Autism Educational Scholarship to be Awarded by San Diego Law Firm

Retrieved on: 
Friday, February 17, 2023
Hope, Han Kun Law Offices, Depression, Privacy, Spectrum, Person, ASD, Policy, Law, DSM-V, Education, SAN, Employment, Nursing, Private investigator

SAN DIEGO, Feb. 17, 2023 /PRNewswire-PRWeb/ -- At the Law Office of David P. Shapiro, a San Diego criminal defense law firm, we are once again offering an educational scholarship in support of individuals who have been diagnosed with autism (autism spectrum disorder or ASD). The $1,000 scholarship award will be used to pay a portion of the tuition at a post-secondary school chosen by the successful applicant.

Key Points: 
  • SAN DIEGO, Feb. 17, 2023 /PRNewswire-PRWeb/ -- At the Law Office of David P. Shapiro , a San Diego criminal defense law firm, we are once again offering an educational scholarship in support of individuals who have been diagnosed with autism (autism spectrum disorder or ASD).
  • The $1,000 scholarship award will be used to pay a portion of the tuition at a post-secondary school chosen by the successful applicant.
  • Our firm is committed to providing opportunities to those with autism to continue their education beyond the high school level.
  • Questions about the scholarship should be directed, via email to:
    Law Office of David P. Shapiro
    Michael, Law Office of David P. Shapiro, 1 619-295-3555, [email protected]
    SOURCE Law Office of David P. Shapiro

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.